Press Releases

Shasqi to Present Data Updates at Upcoming SITC and CTOS Meetings

November 04, 2021

Shasqi announced upcoming presentations at both SITC and CTOS, sharing updated data from its Phase 1 clinical study of SQ3370 in patients with advanced solid tumors, and nonclinical data on SQ3370 in combination with cancer immunotherapies.

Shasqi Announces Click Chemistry Breakthrough with First-Ever Human Application in Launch of Clinical Program

October 14, 2020

First Patients Dosed in Phase 1 Clinical Study of SQ3370 for Advanced Solid Tumor Malignancies. Shasqi is First Y-Combinator Biotech Company to Reach First-in-Human Clinical Studies. SAN FRANCISCO, CA. – October 14, 2020 – Shasqi announced today the first-ever application of click chemistry in humans, with the launch of the Company’s lead clinical candidate, SQ3370.

Shasqi Announces Appointments of Wayne Saville, M.D., as Chief Medical Officer and Juan Jaen, Ph.D., as Member of Board of Directors

October 08, 2020

Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today that the Company has appointed Wayne Saville, M.D., as Chief Medical Officer, and Juan Jaen, Ph.D., President & Co-founder of Arcus Biosciences, as a member of the Shasqi board of directors.

Shasqi Demonstrates Chemistry-based Platform Produces Local and Systemic Anti-tumor Response in Preclinical Cancer Model

June 22, 2020

Shasqi, a leader in chemistry based locally-activated cancer drugs, presented data showing that the company’s lead candidate SQ3370 produced robust anti-tumor responses both at the target site and at distal lesions in a preclinical cancer model. The study, titled “SQ3370, a Local Activation Therapy of Cytotoxic Agents, Produces Sustained Responses in Target and Distal Lesions via Immune Activation,” was presented in a poster with audio at the American Association for Cancer Research Virtual Annual Meeting II.

Shasqi Completes $10 Million Series A Financing

October 31, 2019

Shasqi, Inc., a privately held company focused on improving the localized delivery of cancer drugs to tumors, today announced the completion of a $10 million Series A financing. The proceeds of the financing are being used to complete GMP manufacturing for the company’s lead drug candidate and to support a Phase 1 human trial, expected to commence in Q2 2020.

Shasqi's Local Drug Activation Technology Provides Improved Drug Efficacy with Minimal Side-effects

July 20, 2016

Scientists at Shasqi, Inc. and SUNY University at Albany have published research demonstrating a way to target drugs to specific areas of the body, enabling greater efficacy and fewer side-effects. The method, called local drug activation, uses activating agents in an injected polymer gel to concentrate and activate prodrug versions of a drug, such as a chemotherapeutic, directly at a desired location, limiting the drug's action to that specific site. The researchers recently published their findings online in ACS Central Science, the open-access flagship journal of the American Chemical Society.